Y705 stat3 - PowerPoint PPT Presentation
8 h
2 mM GlcN. A. 0 h. 2 h. 4 h. 8 h. 12 h. 24 h. p(Y705)Stat3. Stat3. Actin. 2 mM GlcN. Controls. B. 1 h. 0 h. 4 h. 8 h. Stat3. 1. 2. 3. 4. 5. 6. 7. 8. C.
By italiaView Y705 stat3 PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Y705 stat3 PowerPoint presentations. You can view or download Y705 stat3 presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.
Recherches associées pour Y705 stat3
p-STAT3 (Y705)
A. B. C. MDA-MB-453. MCF-10A. MCF-10A. + 468 CM 24 hr. + 468 CM 6 hr. + 231 CM 0.5 hr. No Tx. No Tx. Alone. + 453. + 468. p-STAT3 (Y705). p-STAT3 (Y705). p-STAT3 (Y705). STAT3. STAT3. STAT3. Actin. GAPDH. GAPDH. D. E. F. MDA-MB-453. MCF-10A.
STAT3
STAT3. Michael Patel. Overview. STAT3 is a transcription activator It homodimerizes and binds to the DNA promoter region It is associated with oncogenesis, cellular differentiation, and embryogenesis. STAT3 Signaling Pathway. Involved in signal transduction pathway
Vehicle Stat3 siRNA
A. Synthetic siRNA against STAT3. 5’-CAU CUG CCU AGA UCG GCU AdTdT-3’ 3’-dTdT GUA GAC GGA UCU AGC CGA U- 5’. Vehicle Stat3 siRNA GFP siRNA. Vehicle Stat3 siRNA GFP siRNA. Vehicle Stat3 siRNA. B. a -STAT3 a - b -actin. a -STAT3 a -MAPK. A172. U251. NHA. C.
STAT3 Signaling Pathway
STAT3 Signaling Pathway. SIGMA-ALDRICH. STAT3 Signaling Pathway
STAT3 pSTAT3 GAPDH
BCL-2. BCL2. GAPDH. GAPDH. Apoptotic cells (%). Apoptotic cells (%). LN229. miR21i alone. miR21i/PAMAM. U87. （ m m ）. STAT3 pSTAT3 GAPDH. STAT3 pSTAT3 GAPDH. PTEN. 时序控制对替莫唑胺和反义 miR-21 联合作用的研究. 钱小敏 1 任玉 3 史振东 2 柳朝永 1 吉雅茹 1 原续波 1* 康春生 2*. 天津大学材料科学与工程学院，天津 300072
STAT3 and the Immune System
STAT3 and the Immune System. Maureen Sherry Lynes February 29, 2012. Overview. STAT family; STAT3 signaling and structure Role of STAT3 revealed by tissue specific knockouts STAT3 and the anti-tumor immune response Therapeutic approaches for targeting STAT3 Paper discussion.
N-Term. STAT3 (S21320/ 610190)
- UV + UV. C. A. - D - D. AG490 MG. ( m M). 132. - D 1 10 100 50 -. 97.1 kDa -. 102 -. C-Term. C-Term. C-Term. C-Term. C-Term. 67.3 kDa -. 71 -. STAT3 a. STAT3 a. STAT3 a. STAT3 a. STAT3 a. 46 -. Cytopl. 43.9 kDa -. (sc-482). (sc-482). (sc-482).
Read genomic coordinates of STAT3 binding
Cross linking protein/DNA. Cells. Shear DNA strands by sonification. Immunopeecipitation with bead attached anti-STAT3 antibodies . Reverse crosslinks. Sequence. Align to genome . Read genomic coordinates of STAT3 binding. Read miR promoter genomic coordinates. Figure S1.
Read genomic coordinates of STAT3 binding
Cross linking protein/DNA. Cells. Shear DNA strands by sonification. Immunopeecipitation with bead attached anti-STAT3 antibodies. Reverse crosslinks. Sequence. Align to genome. Read genomic coordinates of STAT3 binding. Read miR promoter genomic coordinates. Figure S1.
SHP-1 reverses trastuzumab resistance and migration in HER2-positive breast cancer cells through the stat3/p-stat3 pathw
Decreased expression of Src homology region 2 domain containing protein tyrosine phosphatase 1 (SHP-1) was found in human breast cancer cell lines and primary breast cancers. As a candidate tumor suppressor gene, the role of SHP-1 in HER-2-positive breast cancer remains to be elucidated. The aim of the present study was to investigate the effects of upregulated SHP-1 expression in reversing trastuzumab resistance and migration by HER-2-positive breast cancer cells, potentially providing a new target to trastuzumab resistance in anti-HER2 therapy.